dalteparin has been researched along with Complications, Hematologic Pregnancy in 84 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our results suggest that the use of long-term prophylactic dalteparin in pregnancy is not associated with a significant decrease in BMD." | 9.12 | Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. ( Clement, AM; Cranney, A; Hague, WM; Hodsman, A; Kahn, SR; Kovacs, MJ; Lazo-Langner, A; Rodger, MA, 2007) |
| "Anti-Xa activity levels were used to assess prophylactic (33 women) and therapeutic (15 women) dalteparin dosage throughout pregnancy." | 9.09 | Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. ( Rey, E; Rivard, GE, 2000) |
| "Nine studies, including data of 1228 women, were included in the review evaluating the effect of either LMWH (enoxaparin or nadroparin in varying doses) or aspirin or a combination of both, on the chance of live birth in women with recurrent miscarriage, with or without inherited thrombophilia." | 8.90 | Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. ( de Jong, PG; Di Nisio, M; Goddijn, M; Kaandorp, S; Middeldorp, S, 2014) |
| "Dysfibrinogenemia is caused by a variety of structural abnormalities in the fibrinogen molecule, which results in a tendency for bleeding and thrombosis as well as obstetric complications." | 7.75 | Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. ( Galanakis, D; Miesbach, W; Scharrer, I, 2009) |
| "Data from this retrospective cohort study suggest that combined treatment with dalteparin and ASA decreases the risk of preeclampsia by 20% and the risk of FGR by 30% in women with inherited thrombophilia." | 7.74 | Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. ( David, M; Dubois, E; Leduc, L; Rey, E; Takser, L, 2007) |
| " No adverse maternal-fetal side effects were reported on enoxaparin alone or enoxaparin-metformin." | 6.74 | Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss. ( Glueck, CJ; Goldenberg, N; Khan, N; Ramidi, G; Wang, P, 2009) |
| "Hypercoagulability is observed in patients with inherited thrombophilia, e." | 6.70 | The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation. ( Eberl, E; Geisen, U; Grossmann, R; Keller, F; Schambeck, CM, 2001) |
| "Dalteparin or dextran was used during delivery." | 6.69 | Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study. ( Blombäck, M; Bremme, K; Hellgren, M; Lindberg, H; Siegbahn, A, 1998) |
| "Screening results for thrombophilia and antithrombotic treatment with enoxaparin, aspirin, or both and pregnancy outcomes." | 5.27 | The Prevalence of Thrombophilia in Women With Recurrent Fetal Loss and Outcome of Anticoagulation Therapy for the Prevention of Miscarriages. ( Elias, A; Elias, M; Nahas, R; Saliba, W, 2018) |
| "Our results suggest that the use of long-term prophylactic dalteparin in pregnancy is not associated with a significant decrease in BMD." | 5.12 | Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. ( Clement, AM; Cranney, A; Hague, WM; Hodsman, A; Kahn, SR; Kovacs, MJ; Lazo-Langner, A; Rodger, MA, 2007) |
| " In a randomised open study, 44 pregnant women with confirmed previous or current thromboembolism were randomised to receive either low-molecular-weight heparin, dalteparin (N = 21) once daily subcutaneously or unfractionated sodium heparin (UF heparin, N = 23) twice daily subcutaneously for thromboprophylaxis during pregnancy and puerperium." | 5.10 | Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. ( Hiilesmaa, V; Kaaja, R; Leinonen, P; Markkola, A; Pettilä, V, 2002) |
| "Anti-Xa activity levels were used to assess prophylactic (33 women) and therapeutic (15 women) dalteparin dosage throughout pregnancy." | 5.09 | Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. ( Rey, E; Rivard, GE, 2000) |
| "Nine studies, including data of 1228 women, were included in the review evaluating the effect of either LMWH (enoxaparin or nadroparin in varying doses) or aspirin or a combination of both, on the chance of live birth in women with recurrent miscarriage, with or without inherited thrombophilia." | 4.90 | Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. ( de Jong, PG; Di Nisio, M; Goddijn, M; Kaandorp, S; Middeldorp, S, 2014) |
| "Dysfibrinogenemia is caused by a variety of structural abnormalities in the fibrinogen molecule, which results in a tendency for bleeding and thrombosis as well as obstetric complications." | 3.75 | Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. ( Galanakis, D; Miesbach, W; Scharrer, I, 2009) |
| "Data from this retrospective cohort study suggest that combined treatment with dalteparin and ASA decreases the risk of preeclampsia by 20% and the risk of FGR by 30% in women with inherited thrombophilia." | 3.74 | Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. ( David, M; Dubois, E; Leduc, L; Rey, E; Takser, L, 2007) |
| "Heparin prophylaxis at fixed low doses and possibly aspirin could be efficacious in preventing adverse outcomes in women carrying inherited thrombophilia with previous poor obstetric outcomes." | 3.71 | Preventing adverse obstetric outcomes in women with genetic thrombophilia. ( Brancaccio, V; Colaizzo, D; Di Minno, G; Grandone, E; Margaglione, M; Pavone, G; Sciannamé, N, 2002) |
| " Aspirin, 75 mg daily was given in addition to enoxaparin to women with antiphospholipid syndrome." | 3.70 | Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. ( Blumenfeld, Z; Brenner, B; Hoffman, R; Weiner, Z; Younis, JS, 2000) |
| "Aspirin and heparin have been shown to have potentially beneficial effects on trophoblast implantation." | 2.79 | Low dose aspirin and low-molecular-weight heparin in the treatment of pregnant Libyan women with recurrent miscarriage. ( Adam, I; Ashur, BM; Elbareg, AM; Elmahashi, MO; Essadi, FM, 2014) |
| "Weight-based dosing of tinzaparin failed to achieve therapeutic anticoagulation in the vast majority of women, although clinical outcomes were good." | 2.78 | Weight-adjusted dosing of tinzaparin in pregnancy. ( Gibson, PS; Jiang, X; Mansoor, A; Newell, K; Ross, S; Sam, DX; Tang, S, 2013) |
| " No adverse maternal-fetal side effects were reported on enoxaparin alone or enoxaparin-metformin." | 2.74 | Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss. ( Glueck, CJ; Goldenberg, N; Khan, N; Ramidi, G; Wang, P, 2009) |
| " Using enoxaparin pharmacokinetic parameters to simulate anti-Xa time profiles, we observed that the maintenance of the same doses throughout pregnancy resulted in a progressive reduction in mean and peak anti-Xa activities." | 2.73 | Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy. ( Amoura, Z; Ankri, A; Conard, J; Cornet, A; Costedoat-Chalumeau, N; Dommergues, M; Hulot, JS; Lebaudy, C; Lechat, P; Piette, JC; Serreau, R, 2008) |
| "Hypercoagulability is observed in patients with inherited thrombophilia, e." | 2.70 | The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation. ( Eberl, E; Geisen, U; Grossmann, R; Keller, F; Schambeck, CM, 2001) |
| "Dalteparin or dextran was used during delivery." | 2.69 | Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study. ( Blombäck, M; Bremme, K; Hellgren, M; Lindberg, H; Siegbahn, A, 1998) |
| "Women with thrombophilia have an increased risk of pregnancy loss and possibly other serious obstetric complications, although definition of the magnitude of risk will require prospective longitudinal studies." | 2.42 | Thrombophilia and pregnancy complications. ( Kujovich, JL, 2004) |
| "The third pregnancy was established and sintrom was stopped and replaced by fraxiparine 0." | 2.40 | [Successful prophylaxis in a pregnancy with thrombophilic states]. ( Bogdanova, M; Iankova, Z, 1999) |
| "Thrombophilia was present in 38 (33." | 1.46 | Outcomes of threatened abortions after anticoagulation treatment to prevent recurrent pregnancy loss. ( Amsalem, H; Kalish, Y; Kleinstern, G; Rottenstreich, A, 2017) |
| "These findings suggest that vertebral compression fractures and PPO may be one of the causes of severe back pain in postpartum patients." | 1.42 | Postpartum osteoporosis and vertebral fractures in two patients treated with enoxaparin during pregnancy. ( Cakir, B; Dirikoc, A; Ersoy, R; Ozdemir, D; Tam, AA, 2015) |
| "Among patients with cancer-related VTE, 59." | 1.38 | Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study. ( Blostein, M; Faucher, JP; Gamble, G; Game, M; Gordon, W; Kagoma, PK; Kahn, SR; Komari, N; Laverdière, D; Martineau, J; McLeod, A; Mills, A; Miron, MJ; Schulman, S; Springmann, V; Stewart, JA; Strulovitch, C, 2012) |
| " The primary outcome was change in dosing requirements of LMWH throughout pregnancy as determined by the corresponding antifactor Xa activity peak levels." | 1.37 | Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: single-center experience. ( Chevalier, AB; Hibbard, JU; Kominiarek, MA; Nutescu, EA; Shapiro, NL, 2011) |
| "The incidence of severe pregnancy complications in previous pregnancies was similar in both groups." | 1.37 | Low molecular weight heparin treatment during subsequent pregnancies of women with inherited thrombophilia and previous severe pregnancy complications. ( Gamzu, R; Kupferminc, MJ; Lessing, JB; Many, A; Rimon, E; Sharon, M, 2011) |
| "No reductions were observed in the thrombus size or mean mitral gradient on transesophageal echocardiography (TEE) with 1 week of unfractioned heparin therapy." | 1.37 | Partial thrombus resolution with trofiban in a pregnant woman with mechanical prosthetic mitral valve thrombosis. ( Akcay, AB; Akcay, M; Davutoglu, V; Sen, N; Soydinc, HE; Yuce, M, 2011) |
| "Inherited thrombophilia is associated with thromboembolic events and/or poor obstetric outcome." | 1.33 | Inherited thrombophilia: treatment during pregnancy. ( Caruso, A; De Carolis, S; De Stefano, V; Fatigante, G; Ferrazzani, S; Garofalo, S; Leone, G; Rossi, E, 2006) |
| "Lovenox (enoxaparin sodium) therapy appears to be safe and efficacious for pregnant women who are candidates for either prophylactic or therapeutic heparin." | 1.31 | ACOG Committee Opinion: safety of Lovenox in pregnancy. ( , 2002) |
| "The incidence of adverse events reported could be explained by the high risk profile of the study population." | 1.31 | Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. ( Borel-Derlon, A; Borg, JY; Boudignat, O; Cohen, C; Conard, J; Darmon, JY; Francoual, C; Lepercq, J; Priollet, P; Schved, JF; Tournaire, M; Yvelin, N, 2001) |
| " The mean time for dosage increase was 20." | 1.30 | Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. ( Buchanan, N; Copplestone, A; Doughty, HA; Hughes, G; Hunt, BJ; Kerslake, S; Khamashta, M; Majumdar, G, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (13.10) | 18.2507 |
| 2000's | 46 (54.76) | 29.6817 |
| 2010's | 25 (29.76) | 24.3611 |
| 2020's | 2 (2.38) | 2.80 |
| Authors | Studies |
|---|---|
| Simeone, R | 1 |
| Giacomello, R | 1 |
| Bruno, G | 1 |
| Parco, S | 1 |
| Maximova, N | 1 |
| Martinelli, M | 1 |
| Zito, G | 1 |
| Luppi, S | 1 |
| Cervi, G | 1 |
| Ricci, G | 1 |
| de Jong, PG | 1 |
| Kaandorp, S | 1 |
| Di Nisio, M | 1 |
| Goddijn, M | 1 |
| Middeldorp, S | 1 |
| Makatsaria, AD | 1 |
| Bitsadze, VO | 1 |
| Dolgushina, NV | 1 |
| Lewandowski, K | 1 |
| Balcerzak, A | 1 |
| Kubiaczyk-Paluch, B | 1 |
| Breborowicz, GH | 1 |
| Martinelli, P | 1 |
| Maruotti, GM | 1 |
| Coppola, A | 1 |
| Agangi, A | 1 |
| Paladini, D | 1 |
| Grandone, E | 3 |
| Di Minno, G | 2 |
| Barkagan, ZS | 1 |
| Llau, JV | 1 |
| Hoyas, L | 1 |
| Ezpeleta, J | 1 |
| García-Polit, J | 1 |
| Boda, Z | 1 |
| László, P | 1 |
| Pfliegler, G | 1 |
| Tornai, I | 1 |
| Rejtö, L | 1 |
| Schlammadinger, A | 1 |
| Iankova, Z | 1 |
| Bogdanova, M | 1 |
| Alalaf, SK | 1 |
| Jawad, RK | 1 |
| Muhammad, PR | 1 |
| Ali, MS | 1 |
| Al Tawil, NG | 1 |
| Nasich, LL | 1 |
| Hoffman, R | 3 |
| Keren-Politansky, A | 1 |
| Jabareen, A | 1 |
| Kalish, Y | 2 |
| Schliamser, L | 1 |
| Brenner, B | 6 |
| Nadir, Y | 1 |
| Aleidan, FAS | 1 |
| Aljarba, GA | 1 |
| Aldakhil, AA | 1 |
| Allehyani, BI | 1 |
| Yahia, MA | 1 |
| Alghtani, NE | 1 |
| Badri, M | 1 |
| Alaklabi, AA | 1 |
| Alsuhaibani, A | 1 |
| Crowther, MA | 1 |
| Rottenstreich, A | 1 |
| Amsalem, H | 1 |
| Kleinstern, G | 1 |
| Vianello, A | 1 |
| Vencato, E | 1 |
| Cantini, M | 1 |
| Zanconato, G | 1 |
| Manfrin, E | 1 |
| Zamo, A | 1 |
| Zorzi, F | 1 |
| Mazzi, F | 1 |
| Martinelli, N | 1 |
| Cavaliere, E | 1 |
| Monari, F | 1 |
| Venturelli, D | 1 |
| Ferrara, F | 1 |
| Olivieri, O | 1 |
| De Franceschi, L | 1 |
| Lucania, G | 1 |
| Camiolo, E | 1 |
| Carmina, MG | 1 |
| Fiandaca, T | 1 |
| Indovina, A | 1 |
| Malato, A | 1 |
| Messina, R | 1 |
| Fabbiano, F | 1 |
| Marcenò, R | 1 |
| Elmahashi, MO | 1 |
| Elbareg, AM | 1 |
| Essadi, FM | 1 |
| Ashur, BM | 1 |
| Adam, I | 1 |
| Hauck-Dlimi, B | 1 |
| Zimmermann, R | 1 |
| Eckstein, R | 1 |
| Ringwald, J | 1 |
| Ozdemir, D | 1 |
| Tam, AA | 1 |
| Dirikoc, A | 1 |
| Ersoy, R | 1 |
| Cakir, B | 1 |
| Salim, R | 1 |
| Nachum, Z | 1 |
| Gavish, I | 1 |
| Romano, S | 1 |
| Braverman, M | 1 |
| Garmi, G | 1 |
| Nahas, R | 1 |
| Saliba, W | 1 |
| Elias, A | 1 |
| Elias, M | 1 |
| Ramidi, G | 1 |
| Khan, N | 2 |
| Glueck, CJ | 3 |
| Wang, P | 3 |
| Goldenberg, N | 2 |
| Forsnes, E | 1 |
| Occhino, A | 1 |
| Acosta, R | 1 |
| Miesbach, W | 1 |
| Galanakis, D | 1 |
| Scharrer, I | 1 |
| Salomon, O | 1 |
| Dulitzky, M | 1 |
| Apter, S | 1 |
| Friedrich, E | 1 |
| Hameed, AB | 1 |
| Sudrová, M | 1 |
| Kvasnička, J | 1 |
| Kudrnová, Z | 1 |
| Zenáhlíková, Z | 1 |
| Mazoch, J | 1 |
| Brzežková, R | 1 |
| Akcay, AB | 1 |
| Yuce, M | 1 |
| Akcay, M | 1 |
| Sen, N | 1 |
| Soydinc, HE | 1 |
| Davutoglu, V | 1 |
| Pranikoff, J | 1 |
| Riaz, K | 1 |
| Chavan, K | 1 |
| Raj, P | 1 |
| Umar, M | 1 |
| Kupferminc, MJ | 1 |
| Rimon, E | 1 |
| Many, A | 1 |
| Sharon, M | 1 |
| Lessing, JB | 1 |
| Gamzu, R | 1 |
| Shapiro, NL | 1 |
| Kominiarek, MA | 1 |
| Nutescu, EA | 1 |
| Chevalier, AB | 1 |
| Hibbard, JU | 1 |
| Kahn, SR | 4 |
| Springmann, V | 1 |
| Schulman, S | 1 |
| Martineau, J | 1 |
| Stewart, JA | 1 |
| Komari, N | 1 |
| McLeod, A | 1 |
| Strulovitch, C | 1 |
| Blostein, M | 2 |
| Faucher, JP | 1 |
| Gamble, G | 1 |
| Gordon, W | 1 |
| Kagoma, PK | 1 |
| Miron, MJ | 1 |
| Laverdière, D | 1 |
| Game, M | 1 |
| Mills, A | 1 |
| Figueiró-Filho, EA | 1 |
| de Oliveira, VM | 1 |
| Breda, I | 1 |
| Coelho, LR | 1 |
| Ferreira, CM | 1 |
| Brancaccio, V | 1 |
| Colaizzo, D | 2 |
| Sciannamé, N | 1 |
| Pavone, G | 1 |
| Margaglione, M | 2 |
| Bergmann, JF | 1 |
| Mouly, S | 1 |
| Kaaja, RJ | 1 |
| Ulander, VM | 2 |
| Carp, H | 2 |
| Dolitzky, M | 1 |
| Inbal, A | 1 |
| McLintock, C | 1 |
| North, RA | 1 |
| White, HD | 1 |
| Kujovich, JL | 1 |
| Sieve, L | 1 |
| Lindqvist, PG | 3 |
| Merlo, J | 1 |
| Gris, JC | 2 |
| Marès, P | 2 |
| Dulitsky, M | 1 |
| Younis, J | 1 |
| Sarig, G | 1 |
| Blumenfeld, Z | 2 |
| Leiba, R | 1 |
| Lanir, N | 2 |
| Thamban, S | 1 |
| Opemuyi, IO | 1 |
| Swinhoe, JR | 1 |
| Cochrane, GW | 1 |
| De Carolis, S | 1 |
| Ferrazzani, S | 1 |
| De Stefano, V | 2 |
| Garofalo, S | 1 |
| Fatigante, G | 1 |
| Rossi, E | 2 |
| Leone, G | 1 |
| Caruso, A | 1 |
| Puértolas Ortega, M | 1 |
| Izquierdo Villarroya, B | 1 |
| Oliva Perales, P | 1 |
| Lafuente Ojeda, N | 1 |
| Izquierdo Villarroya, J | 1 |
| Ruiz Pérez, R | 1 |
| Bick, RL | 1 |
| Cappucci, F | 1 |
| Lebaudy, C | 1 |
| Hulot, JS | 1 |
| Amoura, Z | 1 |
| Costedoat-Chalumeau, N | 1 |
| Serreau, R | 1 |
| Ankri, A | 1 |
| Conard, J | 2 |
| Cornet, A | 1 |
| Dommergues, M | 1 |
| Piette, JC | 1 |
| Lechat, P | 1 |
| Luzardo, GE | 1 |
| Karlnoski, RA | 1 |
| Williams, B | 1 |
| Mangar, D | 1 |
| Camporesi, EM | 1 |
| Neveu, S | 1 |
| Tailland, ML | 1 |
| Courtieu, C | 1 |
| Schved, JF | 2 |
| Finkelstein, Y | 1 |
| Aloni, D | 1 |
| Kimia, A | 1 |
| Sommer, R | 1 |
| Sirota, L | 1 |
| Brennand, JE | 1 |
| Walker, ID | 1 |
| Greer, IA | 1 |
| Barjot, P | 1 |
| Beucher, G | 1 |
| Le Querrec, A | 1 |
| Derlon-Borel, A | 1 |
| Herlicoviez, M | 1 |
| Younis, JS | 2 |
| Ohel, G | 1 |
| Haddad, S | 1 |
| Ben-Ami, M | 1 |
| Weiner, Z | 1 |
| Dahlbäck, B | 1 |
| Berndt, N | 1 |
| Khan, I | 1 |
| Gallo, R | 1 |
| Lepercq, J | 1 |
| Borel-Derlon, A | 1 |
| Darmon, JY | 1 |
| Boudignat, O | 1 |
| Francoual, C | 1 |
| Priollet, P | 1 |
| Cohen, C | 1 |
| Yvelin, N | 1 |
| Tournaire, M | 1 |
| Borg, JY | 1 |
| Breddin, HK | 1 |
| Hecking, C | 1 |
| Hendelmeier, M | 1 |
| von Bardeleben, R | 1 |
| Gröschel, K | 1 |
| Schinzel, H | 1 |
| Rodger, MA | 2 |
| Phillips, P | 1 |
| James, AH | 1 |
| Konkle, BA | 1 |
| Gerdsen, F | 1 |
| Luxembourg, B | 1 |
| Langer, F | 1 |
| Bauersachs, R | 1 |
| Lindhoff-Last, E | 1 |
| Isma, N | 1 |
| Svensson, PJ | 1 |
| Lindblad, B | 1 |
| Stenqvist, P | 1 |
| Kaaja, R | 3 |
| Abou-Nassar, K | 1 |
| Kovacs, MJ | 2 |
| Wells, P | 1 |
| Doucette, S | 1 |
| Ramsay, T | 1 |
| Clement, AM | 2 |
| Khurana, R | 1 |
| Mackinnon, K | 1 |
| Solymoss, S | 1 |
| Kingdom, J | 1 |
| Sermer, M | 1 |
| Rey, E | 3 |
| Rodger, M | 1 |
| Cranney, A | 1 |
| Hodsman, A | 1 |
| Lazo-Langner, A | 1 |
| Hague, WM | 1 |
| Leduc, L | 1 |
| Dubois, E | 1 |
| Takser, L | 1 |
| David, M | 1 |
| Hunt, BJ | 1 |
| Doughty, HA | 1 |
| Majumdar, G | 1 |
| Copplestone, A | 1 |
| Kerslake, S | 1 |
| Buchanan, N | 1 |
| Hughes, G | 1 |
| Khamashta, M | 1 |
| Drouet, M | 1 |
| Le Sellin, J | 1 |
| Sabbah, A | 1 |
| Blombäck, M | 2 |
| Bremme, K | 2 |
| Hellgren, M | 1 |
| Siegbahn, A | 1 |
| Lindberg, H | 1 |
| Rivard, GE | 1 |
| Schambeck, CM | 1 |
| Eberl, E | 1 |
| Geisen, U | 1 |
| Grossmann, R | 1 |
| Keller, F | 1 |
| Pettilä, V | 2 |
| Leinonen, P | 2 |
| Ylikorkala, O | 1 |
| Taylor, AA | 1 |
| Markkola, A | 1 |
| Hiilesmaa, V | 1 |
| Antovic, A | 1 |
| He, S | 1 |
| Khalifeh, A | 1 |
| Grantham, J | 1 |
| Byrne, J | 1 |
| Murphy, K | 2 |
| McAuliffe, F | 2 |
| Byrne, B | 2 |
| Ní Ainle, F | 1 |
| Wong, A | 1 |
| Appleby, N | 1 |
| Regan, C | 1 |
| Hassan, T | 1 |
| Milner, M | 1 |
| Sullivan, AO | 1 |
| White, B | 1 |
| O'Donnell, J | 1 |
| Higgins, M | 1 |
| Downey, R | 1 |
| Gibson, PS | 1 |
| Newell, K | 1 |
| Sam, DX | 1 |
| Mansoor, A | 1 |
| Jiang, X | 1 |
| Tang, S | 1 |
| Ross, S | 1 |
| Sharif, S | 1 |
| Hay, CR | 1 |
| Clayton-Smith, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss ,Double Blinded Randomized Controlled Trial .[NCT05237843] | Phase 1 | 70 participants (Anticipated) | Interventional | 2022-03-01 | Not yet recruiting | ||
| Assessing Women's Preferences for Postpartum Thromboprophylaxis: the PREFER-PostPartum[NCT05318547] | 52 participants (Anticipated) | Interventional | 2022-05-13 | Recruiting | |||
| Bemiparin Versus Enoxaparin as Thromboprophylaxis Following Vaginal and Abdominal Deliveries: A Prospective Clinical Trial[NCT01588171] | 7,020 participants (Actual) | Interventional | 2012-05-31 | Completed | |||
| Low Dose Aspirin and Low-molecular-weight Heparin in the Treatment of Pregnant Libyan Women With Recurrent Miscarriage[NCT01917799] | Phase 4 | 150 participants (Anticipated) | Interventional | 2009-01-31 | Recruiting | ||
| Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome[NCT01068795] | 144 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
| [NCT00319176] | 15 participants (Anticipated) | Observational | 2004-04-30 | Completed | |||
| anti10a Levels in Women Treated With LMWH in the Postpartum Period for Preventing Vein Thrombosis Events: A Comparison of Two Doses[NCT02856295] | Phase 4 | 136 participants (Actual) | Interventional | 2021-11-20 | Completed | ||
| Low-molecular-weight Heparin to Prevent Recurrent VTE in Pregnancy: a Randomized Controlled Trial of Two Doses[NCT01828697] | Phase 4 | 1,110 participants (Actual) | Interventional | 2013-04-24 | Completed | ||
| Postpartum Prophylaxis for PE Randomized Control Trial Pilot: A Pilot Study Assessing Feasibility of a Randomized, Open-label Trial of Low-Molecular-Weight-Heparin for Postpartum Prophylaxis in Women at Risk of Developing Venous Thromboembolism[NCT01274637] | Phase 3 | 62 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Effects of UFH and LMWH on Osteoprotegerin and RANKL Plasma Levels in Hemodialysis Patients[NCT00669721] | 40 participants (Anticipated) | Interventional | 2008-03-31 | Recruiting | |||
| Weight-Adjusted Dosing of Tinzaparin in Pregnancy[NCT00851864] | Phase 4 | 13 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"If a subject dies between randomization and late postpartum follow up (Day 90 +/- 7 days) the death will be adjudicated as certain, highly probable, probable, or unlikely due to Pulmonary Embolism (PE) using the following criteria.~Certain: hypotension, hypoxia, cardiac arrest with no other explanation other than PE and autopsy or radiographic confirmation Highly probable: criteria for certain but another disease could have caused the death Probable: other cause suspected based on clinical evidence but 100% certainty not available Unlikely: all other cases." (NCT01274637)
Timeframe: From Randomization to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Molecular Weight Heparin | 0 |
| Control Group | 0 |
The average number of subjects that are recruited per site per month during a 4 month active recruitment phase at each site. (NCT01274637)
Timeframe: 4 months
| Intervention | participants per site per month (Number) |
|---|---|
| Low Molecular Weight Heparin | 0.9 |
| Control Group | 0.9 |
All subjects who develop thrombocytopenia (platelets less than 80 x 109/L and/or with >50% decrease from baseline) will be investigated for Heparin Induced Thrombocytopenia (HIT) by having ELISA and serotonin release assays to confirm or refute a diagnosis of HIT. HIT will be diagnosed with a positive PF4 (platelet factor 4) HIT ELISA assay. (NCT01274637)
Timeframe: From Randomization to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Molecular Weight Heparin | 0 |
| Control Group | 0 |
This includes symptomatic Deep Vein Thrombosis or Pulmonary Embolism. Suspected outcomes will be adjudicated by a blinded adjudication committee. (NCT01274637)
Timeframe: From Day 10 to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Molecular Weight Heparin | 0 |
| Control Group | 0 |
"Major bleeding meets at least one of the following: Fatal bleeding; Symptomatic bleeding in a critical area or organ (intracranial, intraspinal, retroperitoneal, etc.); Bleeding causing a fall in hemoglobin level of 20 g L-1 (1.24 mmol L-1) or more, or leading to transfusion of two or more units of whole blood or red cells .~Clinically Relevant Non-major Bleeding does not meet the criteria for major bleeding but meets at least one of the following: Hospitalization; Medical intervention; Unscheduled contact with a physician; Discomfort (pain, or impairment of activities of daily life)." (NCT01274637)
Timeframe: From Randomization to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Molecular Weight Heparin | 3 |
| Control Group | 1 |
This includes symptomatic Deep Vein Thrombosis (DVT) or pulmonary embolism (PE) in the interval between randomization and the last dose of study drug (10 days +/- 3 days) OR asymptomatic proximal DVT detected by compression ultrasound of both legs done within 24hrs of the last dose of study drug (10 days (+/- 3 days) postpartum). Compressed and non-compressed images will be obtained from the calf trifurcation to the inguinal ligament. All suspected outcomes will be adjudicated by a blinded expert adjudication committee. (NCT01274637)
Timeframe: From randomization to Day 10
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Molecular Weight Heparin | 0 |
| Control Group | 0 |
8 reviews available for dalteparin and Complications, Hematologic Pregnancy
| Article | Year |
|---|---|
Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia.
Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Enoxaparin; Female; Heparin, | 2014 |
Use of the low-molecular-weight heparin nadroparin during pregnancy. A review.
Topics: Antiphospholipid Syndrome; Female; Fibrinolytic Agents; Heart Valve Prosthesis; Herpes Simplex; Huma | 2003 |
[Successful prophylaxis in a pregnancy with thrombophilic states].
Topics: Acenocoumarol; Adult; Anticoagulants; Drug Therapy, Combination; Female; Gravidity; Humans; Nadropar | 1999 |
Thromboprophylaxis in medical patients: focus on France.
Topics: Acute Disease; Adult; Aged; Attitude of Health Personnel; Cardiovascular Diseases; Double-Blind Meth | 2002 |
Thrombophilia and pregnancy complications.
Topics: Abortion, Habitual; Enoxaparin; Factor V; Female; Fetal Growth Retardation; Fibrinolytic Agents; Hum | 2004 |
Gestational thrombocythaemia associated with intrauterine death: case report and a review of the literature.
Topics: Anticoagulants; Enoxaparin; Female; Fetal Death; Humans; Placenta; Placenta Diseases; Pregnancy; Pre | 2006 |
Antiphospholipid syndrome in pregnancy.
Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin | 2008 |
Reviparin sodium - a new low molecular weight heparin.
Topics: Absorption; Anticoagulants; Child; Drug Evaluation; Factor Xa Inhibitors; Female; Heparin, Low-Molec | 2002 |
22 trials available for dalteparin and Complications, Hematologic Pregnancy
| Article | Year |
|---|---|
Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial.
Topics: Adult; Anticoagulants; Cesarean Section; Enoxaparin; Female; Hematoma; Heparin, Low-Molecular-Weight | 2015 |
Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial.
Topics: Adult; Anticoagulants; Cesarean Section; Enoxaparin; Female; Hematoma; Heparin, Low-Molecular-Weight | 2015 |
Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial.
Topics: Adult; Anticoagulants; Cesarean Section; Enoxaparin; Female; Hematoma; Heparin, Low-Molecular-Weight | 2015 |
Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial.
Topics: Adult; Anticoagulants; Cesarean Section; Enoxaparin; Female; Hematoma; Heparin, Low-Molecular-Weight | 2015 |
Low dose aspirin and low-molecular-weight heparin in the treatment of pregnant Libyan women with recurrent miscarriage.
Topics: Abortion, Habitual; Adult; Aspirin; Birth Weight; Embryo Implantation; Enoxaparin; Female; Fibrinoly | 2014 |
Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial.
Topics: Adult; Anticoagulants; Birth Weight; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Infant, Newbo | 2016 |
The Prevalence of Thrombophilia in Women With Recurrent Fetal Loss and Outcome of Anticoagulation Therapy for the Prevention of Miscarriages.
Topics: Abortion, Habitual; Adolescent; Adult; Anticoagulants; Aspirin; Enoxaparin; Female; Humans; Middle A | 2018 |
Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss.
Topics: Abortion, Habitual; Abortion, Spontaneous; Adult; Anticoagulants; Blood Coagulation Disorders; Dose- | 2009 |
Influence of long-term thromboprophylaxis with low-molecular-weight heparin (enoxaparin) on changes of bone metabolism markers in pregnant women.
Topics: Adult; Alkaline Phosphatase; Anticoagulants; Bone and Bones; Enoxaparin; Female; Gestational Age; Hu | 2011 |
High factor XI, recurrent pregnancy loss, enoxaparin.
Topics: Abortion, Habitual; Anticoagulants; Cohort Studies; Embryo Loss; Enoxaparin; Factor XI; Female; Homo | 2010 |
Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia.
Topics: Abortion, Habitual; Adult; Birth Rate; Enoxaparin; Family Health; Female; Fibrinolytic Agents; Human | 2003 |
Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin.
Topics: Abortion, Habitual; Abortion, Spontaneous; Adult; Blood Coagulation Disorders; Case-Control Studies; | 2004 |
Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study.
Topics: Abortion, Habitual; Dose-Response Relationship, Drug; Drug Hypersensitivity; Enoxaparin; Female; Hem | 2005 |
Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss.
Topics: Abortion, Habitual; Adult; Anticoagulants; Enoxaparin; Female; Fibrin Fibrinogen Degradation Product | 2005 |
Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Gestational Age; Humans; Metabolic Clearance Rate; Postpa | 2008 |
Use of a low-molecular weight heparin (enoxaparin) or of a phenformin-like substance (moroxydine chloride) in primary early recurrent aborters with an impaired fibrinolytic capacity.
Topics: Abortion, Habitual; Adult; Biguanides; Double-Blind Method; Enoxaparin; Female; Fibrinolysis; Humans | 1995 |
Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial.
Topics: Adult; Anticoagulants; Dalteparin; Double-Blind Method; Drug Administration Schedule; Feasibility St | 2015 |
The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial.
Topics: Adult; Anticoagulants; Antithrombin III; Biomarkers; Blood Coagulation; Dalteparin; Female; Heparin, | 2007 |
Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial.
Topics: Adult; Anticoagulants; Bone Density; Bone Diseases, Metabolic; Dalteparin; Female; Humans; Middle Ag | 2007 |
Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study.
Topics: Adult; Dalteparin; Drug Administration Schedule; Female; Humans; Longitudinal Studies; Pregnancy; Pr | 1998 |
Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin.
Topics: Adult; Anticoagulants; Body Mass Index; Body Weight; Dalteparin; Drug Monitoring; Female; Follow-Up | 2000 |
The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation.
Topics: Adult; Anticoagulants; Case-Control Studies; Dalteparin; Factor V; Female; Hemostasis; Hemostatics; | 2001 |
Increased thromboxane production in women with a history of venous thromboembolic event: effect of heparins.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Analysis of Variance; Anticoagulants; Body Mass Index; Case-Con | 2001 |
Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin.
Topics: Absorptiometry, Photon; Adult; Anticoagulants; Bone Density; Dalteparin; Factor Xa Inhibitors; Femal | 2002 |
Weight-adjusted dosing of tinzaparin in pregnancy.
Topics: Adult; Body Weight; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Heparin, Low-Mole | 2013 |
54 other studies available for dalteparin and Complications, Hematologic Pregnancy
| Article | Year |
|---|---|
Thrombogenesis in Thrombophilic Pregnancy: Evaluation of Low-Molecular-Weight Heparin Prophylaxis.
Topics: Adult; Anticoagulants; Case-Control Studies; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-We | 2017 |
[Successful pregnancy outcome in the woman with thrombophilia and multiple miscarriages].
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Cesarean Section; Factor V; Female; Heterozygote | 2003 |
Pregnancy in a woman with a history of Budd-Chiari syndrome treated by porto-systemic shunt, protein C deficiency and bicornuate uterus.
Topics: Adult; Anticoagulants; Budd-Chiari Syndrome; Female; Humans; Labor, Induced; Nadroparin; Portasystem | 2006 |
[The use of fraxiparin for the prevention and treatment of thromboembolism in patients with heparin-induced thrombocytopenia].
Topics: Adult; Disseminated Intravascular Coagulation; Drug Evaluation; Female; Heparin; Humans; Male; Middl | 1993 |
[Use of low molecular weight heparins].
Topics: Anesthesia, Epidural; Anesthesia, Obstetrical; Anticoagulants; Antithrombin III Deficiency; Cesarean | 1997 |
[Thrombophilia, anticoagulant therapy and pregnancy].
Topics: Adult; Anticoagulants; Female; Heparin, Low-Molecular-Weight; Humans; Maternal Mortality; Nadroparin | 1998 |
Effects of anti-Xa activity monitoring on the outcome of high-risk pregnancies treated with a prophylactic dose of low-molecular-weight heparin.
Topics: Anticoagulants; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Infant, Newborn; Pregnanc | 2023 |
A prospective cohort study comparing achieved anti-factor Xa peak levels in pregnant and non-pregnant patients receiving therapeutic-dose low-molecular-weight heparin.
Topics: Adult; Anticoagulants; Biomarkers; Body Mass Index; Cohort Studies; Drug Monitoring; Enoxaparin; Fac | 2020 |
Outcomes of threatened abortions after anticoagulation treatment to prevent recurrent pregnancy loss.
Topics: Abortion, Habitual; Abortion, Threatened; Adult; Anticoagulants; Enoxaparin; Female; Humans; Live Bi | 2017 |
Improvement of maternal and fetal outcomes in women with sickle cell disease treated with early prophylactic erythrocytapheresis.
Topics: Abortion, Spontaneous; Adult; Anemia, Sickle Cell; Anticoagulants; Birth Weight; Cross-Sectional Stu | 2018 |
Multidisciplinary approach in pregnancy-associated thrombotic thrombocytopenic purpura: a case report.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Cesarean Section; Combined Modality T | 2014 |
Two successful pregnancies in a carrier of heterozygous factor V LEIDEN mutation with aplasia of the inferior vena cava and a history of proximal deep venous thrombosis.
Topics: Anticoagulants; Enoxaparin; Factor V; Female; Heterozygote; Humans; Iliac Vein; Live Birth; Mutation | 2014 |
Postpartum osteoporosis and vertebral fractures in two patients treated with enoxaparin during pregnancy.
Topics: Absorptiometry, Photon; Adult; Anticoagulants; Bone Density; Enoxaparin; Female; Fractures, Compress | 2015 |
Spontaneous spinal epidural hematoma in pregnancy associated with using low molecular weight heparin.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Cesarean Section; Enoxaparin; Female; Hematoma, Ep | 2009 |
Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy.
Topics: Abortion, Habitual; Abruptio Placentae; Adult; Afibrinogenemia; Enoxaparin; Female; Fibrinogen; Fibr | 2009 |
New observations in postpartum ovarian vein thrombosis: experience of single center.
Topics: Adult; Anticoagulants; Aspirin; Cesarean Section; Early Diagnosis; Enoxaparin; Female; Humans; Incid | 2010 |
Fluctuations in anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy.
Topics: Adult; Cross-Sectional Studies; Drug Administration Schedule; Drug Monitoring; Enoxaparin; Factor Xa | 2010 |
Partial thrombus resolution with trofiban in a pregnant woman with mechanical prosthetic mitral valve thrombosis.
Topics: Adult; Echocardiography, Transesophageal; Enoxaparin; Female; Fibrinolytic Agents; Heart Valve Prost | 2011 |
Low molecular weight heparin treatment during subsequent pregnancies of women with inherited thrombophilia and previous severe pregnancy complications.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complications; Pregnancy Com | 2011 |
Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: single-center experience.
Topics: Academic Medical Centers; Adult; Anticoagulants; Body Weight; Cohort Studies; Dalteparin; Dose-Respo | 2011 |
Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study.
Topics: Adult; Aged; Anticoagulants; Canada; Catheterization; Coumarins; Disease Management; Drug Utilizatio | 2012 |
[Usefulness of a scoring system on perinatal outcomes in pregnant women with thrombophilia in the effectiveness of an enoxaparin-based intervention].
Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complications, Hematologic; | 2012 |
Preventing adverse obstetric outcomes in women with genetic thrombophilia.
Topics: Aspirin; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Pregnancy; Pregnancy Complication | 2002 |
ACOG Committee Opinion: safety of Lovenox in pregnancy.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complications, Hematologic; Safety | 2002 |
Treatment of acute pulmonary embolism during pregnancy with low molecular weight heparin: three case reports.
Topics: Acute Disease; Adult; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregnanc | 2002 |
Prosthetic heart valves and pregnancy.
Topics: Abnormalities, Drug-Induced; Anticoagulants; Enoxaparin; Female; Heart Valve Prosthesis; Humans; Pre | 2003 |
Low molecular weight heparin for repeated pregnancy loss: is it based on solid evidence?
Topics: Abortion, Habitual; Clinical Protocols; Clinical Trials as Topic; Enoxaparin; Female; Heparin, Low-M | 2005 |
The long and winding road ... towards LMWH for pregnancy loss.
Topics: Abortion, Habitual; Clinical Protocols; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; P | 2005 |
Thrombophilia and pregnancy loss in first intended pregnancy.
Topics: Abortion, Habitual; Abortion, Spontaneous; Enoxaparin; Female; Gravidity; Humans; Pregnancy; Pregnan | 2005 |
Inherited thrombophilia: treatment during pregnancy.
Topics: Adult; Anticoagulants; Birth Weight; Cesarean Section; Delivery, Obstetric; Enoxaparin; Female; Feta | 2006 |
[Analgesia for childbirth in a patient with factor V Leiden mutation].
Topics: Activated Protein C Resistance; Adult; Analgesia, Epidural; Analgesia, Obstetrical; Anticoagulants; | 2007 |
Antithrombotic prophylaxis during pregnancy in women with deficiency of natural anticoagulants.
Topics: Abortion, Habitual; Adult; Anticoagulants; Cohort Studies; Enoxaparin; Female; Humans; Live Birth; P | 2008 |
Anesthetic management of a parturient with hyperhomocysteinemia.
Topics: Adult; Anesthesia, Spinal; Anesthetics, Inhalation; Anticoagulants; Blood Coagulation; Blood Coagula | 2008 |
Deep venous thrombosis in a preterm newborn of a mother with activated protein C resistance.
Topics: Adult; Blood Coagulation Disorders; Enoxaparin; Female; Humans; Infant, Newborn; Infant, Premature, | 1998 |
Anti-activated factor X profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin.
Topics: Adult; Anticoagulants; Enoxaparin; Factor Xa; Female; Humans; Pregnancy; Pregnancy Complications, He | 1999 |
[Resistance to activated protein C and pregnancy: thromboprophylaxis with low molecular weight heparin].
Topics: Activated Protein C Resistance; Adult; Anticoagulants; Enoxaparin; Factor V; Female; Humans; Point M | 1999 |
The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation.
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Factor V; | 2000 |
Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.
Topics: 3' Untranslated Regions; Abortion, Habitual; Activated Protein C Resistance; Adult; Anticoagulants; | 2000 |
Bleeding complications associated with low molecular weight heparin prophylaxis during pregnancy.
Topics: Anemia; Anticoagulants; Dalteparin; Delivery, Obstetric; Dextrans; Enoxaparin; Female; Hemorrhage; H | 2000 |
A complication in anticoagulation using low-molecular weight heparin in a patient with a mechanical valve prosthesis. A case report.
Topics: Adult; Anticoagulants; Dilatation and Curettage; Enoxaparin; Female; Heart Valve Prosthesis; Heart V | 2000 |
Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies.
Topics: Adult; Anticoagulants; Cerebral Hemorrhage; Enoxaparin; Female; Humans; Infant, Newborn; Intracrania | 2001 |
Recurrent cerebral ischaemia in a pregnant woman with patent foramen ovale II° and thrombophilia.
Topics: Adult; Anticoagulants; Brain Ischemia; Dalteparin; Female; Foramen Ovale, Patent; Humans; Injections | 2014 |
A prospective analysis of heparin-platelet factor 4 antibodies in pregnant women treated with the low-molecular-weight heparin, dalteparin.
Topics: Adult; Antibody Specificity; Antigens, Human Platelet; Autoantibodies; Autoantigens; Dalteparin; Dos | 2008 |
The effect of low molecular weight heparin (dalteparin) on duration and initiation of labour.
Topics: Adult; Anticoagulants; Case-Control Studies; Chi-Square Distribution; Dalteparin; Female; Gestationa | 2010 |
Treatment of deep venous thrombosis with low-molecular-weight heparin during pregnancy.
Topics: Adult; Dalteparin; Drug Evaluation; Female; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Huma | 2002 |
Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia.
Topics: Abruptio Placentae; Adult; Anticoagulants; Aspirin; Dalteparin; Drug Therapy, Combination; Female; F | 2007 |
Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies.
Topics: Adult; Anticoagulants; Dalteparin; Female; Humans; Injections, Subcutaneous; Pregnancy; Pregnancy Co | 1997 |
[Does the pork/cat syndrome constitute a predisposition to heparin allergy?].
Topics: Adult; Allergens; Animals; Asthma; Blotting, Western; Cats; Cross Reactions; Dalteparin; Drug Erupti | 1997 |
Successful use of heparinoids in a pregnancy complicated by allergy to heparin.
Topics: Adult; Anticoagulants; Chondroitin Sulfates; Dalteparin; Dermatan Sulfate; Drug Combinations; Drug H | 2001 |
The assay of overall haemostasis potential used to monitor the low molecular mass (weight) heparin, dalteparin, treatment in pregnant women with previous thromboembolism.
Topics: Adult; Anticoagulants; Biomarkers; Blood Coagulation Tests; Dalteparin; Factor Xa Inhibitors; Female | 2002 |
Tinzaparin safety and efficacy in pregnancy.
Topics: Abortion, Habitual; Adolescent; Adult; Drug Hypersensitivity; Female; Fibrinolytic Agents; Hemorrhag | 2014 |
Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy.
Topics: Adult; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fibri | 2008 |
Tinzaparin failure in a pregnant patient with a mitral metal valve.
Topics: Adult; Female; Fibrinolytic Agents; Heart Valve Prosthesis; Heparin, Low-Molecular-Weight; Humans; P | 2008 |
Aplasia cutis congenita and low molecular weight heparin.
Topics: Abnormalities, Drug-Induced; Adult; Ectodermal Dysplasia; Female; Fibrinolytic Agents; Heparin, Low- | 2005 |